Point-of-care CAR-T shows ‘promising’ efficacy, safety for B-cell non-Hodgkin lymphoma

Early phase 1 trial results using a novel chimeric antigen receptor T-cell therapy manufactured at University of Colorado show encouraging efficacy for adults with relapsed or refractory B-cell non-Hodgkin lymphoma.